222 related articles for article (PubMed ID: 33821693)
1. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
Trojano M; Ramió-Torrentà L; Grimaldi LM; Lubetzki C; Schippling S; Evans KC; Ren Z; Muralidharan KK; Licata S; Gafson AR
Mult Scler; 2021 Dec; 27(14):2240-2253. PubMed ID: 33821693
[TBL] [Abstract][Full Text] [Related]
2. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N;
Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
[TBL] [Abstract][Full Text] [Related]
3. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M;
Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.
Butzkueven H; Licata S; Jeffery D; Arnold DL; Filippi M; Geurts JJ; Santra S; Campbell N; Ho PR;
BMJ Open; 2020 Oct; 10(10):e038861. PubMed ID: 33082194
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
Hemmer B; Wiendl H; Roth K; Wessels H; Höfler J; Hornuss C; Liedert B; Selmaj K
JAMA Neurol; 2023 Mar; 80(3):298-307. PubMed ID: 36689214
[TBL] [Abstract][Full Text] [Related]
7. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Perumal J; Balabanov R; Su R; Chang R; Balcer L; Galetta S; Campagnolo DI; Avila R; Lee L; Rutledge D; Fox RJ
Adv Ther; 2021 Jul; 38(7):3724-3742. PubMed ID: 34014549
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
Plavina T; Fox EJ; Lucas N; Muralidharan KK; Mikol D
J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603
[TBL] [Abstract][Full Text] [Related]
10. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
van Kempen ZLE; Hoogervorst ELJ; Wattjes MP; Kalkers NF; Mostert JP; Lissenberg-Witte BI; de Vries A; Ten Brinke A; van Oosten BW; Barkhof F; Teunissen CE; Uitdehaag BMJ; Rispens T; Killestein J
Neurology; 2020 Aug; 95(6):e745-e754. PubMed ID: 32690785
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab extended-interval dosing in a real-life setting.
Jeantin L; Boudot de la Motte M; Deschamps R; Gueguen A; Gout O; Lecler A; Papeix C; Bensa C
J Neurol Sci; 2023 Jul; 450():120689. PubMed ID: 37210938
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
13. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
Johnsson M; Farman HH; Blennow K; Zetterberg H; Malmeström C; Axelsson M; Lycke J
Mult Scler; 2022 Nov; 28(13):2070-2080. PubMed ID: 35856574
[TBL] [Abstract][Full Text] [Related]
14. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
16. No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).
Butzkueven H; Kappos L; Spelman T; Trojano M; Wiendl H; Su R; Liao S; Hyde R; Licata S; Ho PR; Campbell N
Ther Adv Neurol Disord; 2021; 14():17562864211042458. PubMed ID: 34603507
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
18. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
19. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
[TBL] [Abstract][Full Text] [Related]
20. A controlled trial of natalizumab for relapsing multiple sclerosis.
Miller DH; Khan OA; Sheremata WA; Blumhardt LD; Rice GP; Libonati MA; Willmer-Hulme AJ; Dalton CM; Miszkiel KA; O'Connor PW;
N Engl J Med; 2003 Jan; 348(1):15-23. PubMed ID: 12510038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]